American Journal of Obstetrics & Gynecology
Volume 199, Issue 5 , Pages 543.e1-543.e7, November 2008

GATA3 expression in estrogen receptor α-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival

  • Ingeborg B. Engelsen, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
    • Institute of Clinical Medicine, University of Bergen, Bergen, Norway
    • Corresponding Author InformationReprints: Ingeborg Bøe Engelsen, MD, Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway
    • ,
  • Ingunn M. Stefansson, MD, PhD

      Affiliations

    • Department of Pathology, Haukeland University Hospital, Bergen, Norway
    • ,
  • Lars A. Akslen, MD, PhD

      Affiliations

    • Department of Pathology, Haukeland University Hospital, Bergen, Norway
    • Gade Institute, University of Bergen, Bergen, Norway
    • ,
  • Helga B. Salvesen, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
    • Institute of Clinical Medicine, University of Bergen, Bergen, Norway

Received 30 November 2007; received in revised form 4 March 2008; accepted 29 April 2008. published online 04 July 2008.

Objective

The transcription factor GATA3 has recently been found to be involved in the carcinogenesis for numerous cancers. We investigated this marker in relation to clinicopathologic characteristics, hormone receptors, other biomarkers, and survival in endometrial carcinoma.

Study Design

A population-based study of 316 endometrial carcinomas with complete follow-up was studied for GATA3, estrogen receptor (ER)-α, ERβ2, and progesterone receptor (PR) expression.

Results

Positive GATA3 expression in hysterectomy specimens significantly correlated to high International Federation of Gynecology and Obstetrics stage, serous papillary/clear cell subtypes, high histologic grade, loss of PR expression, aneuploidy, high proliferation, pathologic p53 and p16 expression, and poor prognosis (P = .003). Loss of hormone receptors significantly correlated with aggressive phenotype and poor prognosis. Pathologic expression of GATA3/ERα in combination added independent prognostic information.

Conclusion

GATA3 expression is associated with an aggressive phenotype and adds independent prognostic information in addition to receptor status. Further studies of its value in tailored treatment protocols seem justified.

Key words: endometrial carcinoma, estrogen receptor-β2(cx), GATA3, prognostic markers, steroid receptors, survival

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The study was supported by Helse Vest grants 911069 and 911351 and the Norwegian Cancer Society.

 Cite this article as: Engelsen IB, Stefansson IM, Akslen LA, et al. GATA3 expression in estrogen receptor α-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 2008;199:543.e1-543.e7.

PII: S0002-9378(08)00493-6

doi:10.1016/j.ajog.2008.04.043

American Journal of Obstetrics & Gynecology
Volume 199, Issue 5 , Pages 543.e1-543.e7, November 2008

Article Tools

* Image Usage & Resolution